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Type 2 Diabetes Mellitus (T2DM) is a chronic inflammatory disorder that is characterized
by chronic hyperglycemia and impaired insulin signaling which in addition to be caused
by common metabolic dysregulations, have also been associated to changes in various
immune cell number, function and activation phenotype. Obesity plays a central role
in the development of T2DM. The inflammation originating from obese adipose tissue
develops systemically and contributes to insulin resistance, beta cell dysfunction and
hyperglycemia. Hyperglycemia can also contribute to chronic, low-grade inflammation
resulting in compromised immune function. In this review, we explore how the trafficking
of innate and adaptive immune cells under inflammatory condition is dysregulated in
T2DM. We particularly highlight the obesity-related accumulation of leukocytes in the
adipose tissue leading to insulin resistance and beta-cell dysfunction and resulting
in hyperglycemia and consequent changes of adhesion and migratory behavior of
leukocytes in different vascular beds. Thus, here we discuss how potential therapeutic
targeting of leukocyte trafficking could be an efficient way to control inflammation as well
as diabetes and its vascular complications.
Keywords: therapies, inflammation, type 2 diabetes, obesity, trafficking, leukocyte
INTRODUCTION
Inflammation is a protective response against harmful stimuli such as injuries, infections and
toxins, which requires the trafficking of leukocytes from the blood stream to the site of
inflammation within damaged tissues. This process is critical for elimination of harmful stimuli and
for tissue repair and is tightly regulated by a variety of mediators such as cell adhesion molecules,
cytokines and chemokines (Wright and Cooper, 2014). Leukocyte behavior and their recruitment to
tissues is modified under inflammatory conditions such as in Type 2 diabetes (T2DM) (Wu et al.,
2011). T2DM is a chronic inflammatory disorder characterized by hyperglycemia and impaired
insulin signaling and production (Calle and Fernandez, 2012). Components of the immune
system are altered in T2DM, with the most apparent changes occurring in the adipose tissue, the
pancreatic islets, the vasculature and in circulating leukocytes (Donath and Shoelson, 2011; Mraz
and Haluzik, 2014; Eguchi and Nagai, 2017). Indeed, cellular stresses, such as oxidative stress and
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lipotoxicity cause insulin resistance and pancreatic islets
dysfunction, can induce an inflammatory response and also
be exacerbated by local inflammation. Patients with T2D have
elevated levels of inflammatory cytokines (such as IL-1β and IL-6)
and chemokines (such as CCL2, CXCL8) (Donath and Shoelson,
2011). This rise in inflammatory mediators completely modifies
leukocyte behavior and recruitment into tissues, which in turn
contributes to maintenance of insulin resistance, loss of insulin
secretion and accelerates development of micro and macro-
vascular complications (Wu et al., 2011). Clinical studies show
that targeting inflammation using small molecules or biological
agents to turn off pro-inflammatory cytokines, deplete immune
cells or block regulatory surface receptors, results in improved
blood glucose levels and insulin sensitivity (Larsen et al.,
2007; Donath and Shoelson, 2011). Obesity, particularly visceral
adiposity, is a major risk factor for T2DM (Donath and Shoelson,
2011) and the adipose tissue of patients with T2DM and/or obese
patients appears to be a major site of inflammation (Lontchi-
Yimagou et al., 2013). Both innate and adaptive immune cells
present in the adipose tissue have critical roles in the regulation of
metabolic homeostasis. Dysregulated trafficking of leukocytes is
observed in the adipose tissue and is associated with a shift in cell
populations from an anti-inflammatory to a pro-inflammatory
profile in obesity (Esser et al., 2014). This switch to a production
of pro-inflammatory cytokines leads to the development of
systemic low-grade inflammation, which results in impaired
insulin signaling, beta-cell dysfunction and subsequent insulin
resistance (Esser et al., 2014). Hyperglycemia rises as the
pancreas fails to compensate insulin resistance (Donath and
Shoelson, 2011). Hyperglycemia then leads to oxidative stress and
induces systemic inflammation by stimulating the production of
inflammatory cytokines (Noshita et al., 2002; Dimayuga et al.,
2007) and chemokines, resulting in endothelial dysfunction
(Nguyen et al., 2012). This review will summarize how T2DM-
related changes in the expression of adhesion molecules and
chemokine receptors/ligands drive endothelial dysfunction and
dysregulates leukocyte trafficking under inflammatory conditions
which ultimately leads to diabetic complications (Figure 1).
THE MOLECULAR PROCESSES OF
LEUKOCYTE RECRUITMENT IN
INFLAMMATION
Recruitment of leukocytes is triggered by the local release
of inflammatory mediators such as histamine, tumor necrosis
factor-alpha (TNFα) and interferon-gamma (IFNγ) in inflamed
tissue (Liu et al., 2004; Zhang et al., 2011; Muller, 2013). These
mediators induce the expression of specific adhesion receptors
such as selectins, adhesion molecules and chemokines, which are
expressed or presented at the surface of endothelial cells (ECs)
and bind to integrins or chemokine receptors located at the
surface of leukocytes (Zhang et al., 2011). Selectins interaction
with their ligands results in leukocyte tethering and rolling
from rapidly flowing blood (Kansas, 1996; Harjunpää et al.,
2019). Selectins are transmembrane calcium-dependent lectins
that consist of three functionally different adhesion molecules
expressed by ECs (E-selectin), platelets and ECs (P-selectin) and
leukocytes (L-selectin) (McEver, 2015). L-selectin and P-selectin
mediate fast rolling of leukocyte through sequential interactions
with their ligands. However, slow rolling events are mediated
by E-selectin on ECs binding to E-selectin ligand-1 (ESL-1) or
P-selectin glycoprotein ligand 1 (PSGL-1) on leukocytes (Yago
et al., 2010). Leukocyte arrest and migration on the endothelium
depends on chemokines (Luu et al., 2000). The shift from
fast rolling to slow rolling allows G-protein-coupled receptors
(GPCRs) on leukocytes to bind to the chemokines expressed on
the surface of ECs, which induces leukocyte integrin activation
and enables leukocyte firm adhesion to the vessel wall (Giagulli
et al., 2004; Rutledge and Muller, 2020). Integrins are a family
of transmembrane receptors expressed by leukocytes. Both α4β1
integrin or very late antigen-4 (VLA-4) and αMβ2 integrin or
lymphocyte function-associated antigen-1 (LFA-1) have been
found to play a role in leukocyte arrest (Uotila et al., 2014).
αMβ2 is expressed on leukocytes as a resting low affinity state.
Conformational changes are required for integrins to switch from
a low affinity state to an active high affinity state enabling them
to bind to their ligands expressed on the endothelium (Kim
et al., 2003; Ley et al., 2007; Fan and Ley, 2015). The activation
of integrins is mediated by chemokines and results in integrin
extension and changes in the cytoskeleton of leukocytes, enabling
tight adhesion on the vessel wall (Rutledge and Muller, 2020).
LFA-1 and VLA-4 on leukocytes, bind to their respective ligand
ICAM-1 and VCAM-1 on ECs, mediate leukocyte adhesion
(Hyduk et al., 2007; Kuwano et al., 2010) and induce intracellular
signals to allow leukocyte arrest (Giagulli et al., 2006; Kummer
and Ebnet, 2018). Leukocytes then extend lamellipodia and
prepare for transendothelial migration (Rutledge and Muller,
2020). Additional downstream signals such as prostaglandin-
D2 (PGD2) signals are required for shape change and dynamic
transmigration of activated leukocytes (Ahmed et al., 2011).
Macrophage integrin-1 (Mac-1) or CD11b/CD18, also known
as αMβ2, interaction with ICAM-1 expressed by the inflamed
endothelium is required for the transition of leukocytes from
tight adhesion to crawling along the vessel wall (leukocyte
locomotion) to then find a suitable site for transendothelial
migration (Schenkel et al., 2004). Leukocytes either transmigrate
(diapedesis) through the endothelial junctions (paracellular
route), or through the body of the ECs (transcellular route)
(Ley et al., 2007). In the paracellular route, the distribution of
junctional molecules is modified in inflamed ECs in a way that
facilitates transendothelial cell migration (Shaw et al., 2001).
Junctional molecules such as platelet/endothelial-cell adhesion
molecule 1 (PECAM-1) and junctional adhesion molecule A
(JAM-A) may support leukocyte migration through mobilizing
to the luminal surface where they can bind to their ligands
expressed on leukocytes and guide them to the junctions (Muller,
2003). JAM-A interaction with αLβ2 allows strong adhesion of
activated leukocyte to the endothelium (Kummer and Ebnet,
2018). PECAM-1 is expressed at EC junctions and leukocytes
(Newman et al., 1990). When leukocytes reach the site of
transmigration, the homophilic interactions between PECAM-
1 on leukocytes with PECAM-1 on the endothelium causes
a transient increase in cytosolic calcium in ECs which guide
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FIGURE 1 | Obesity-related dysregulation of leukocyte trafficking in T2DM. Adipose tissue from lean individuals is characterized by increased numbers of
anti-inflammatory M2 macrophages and higher presence of regulatory T-cells (Tregs). Obesity induces adipose tissue enrichment of cytotoxic CD8+ T-cells and
pro-inflammatory M1 macrophages with a shift from an anti-inflammatory to a pro-inflammatory state. In obesity, the imbalance among leukocytes results in
production of inflammatory cytokines (TNFα, IFNγ, IL-1β) and chemokines which promote systemic inflammation and peripheral insulin resistance as well as beta-cell
dysfunction. Hyperglycemia occurs as a result of beta-cells failure to compensate for insulin resistance. Hyperglycemia exacerbates systemic inflammation by
inducing pro-inflammatory cytokines production and modulating leukocyte trafficking through alteration of the expression of adhesion molecules, chemokines and
chemokine receptors in different vascular beds, which ultimately results in vascular complications.
the leukocytes to the junctions (Ley, 2007; Muller, 2011). Like
PECAM-1, CD99 (Schenkel et al., 2002) and CD99L2, expressed
at EC junctions and on leukocytes, rely on a homophilic
interactions to promote leukocyte extravasation (Schenkel et al.,
2002; Seelige et al., 2013; Rutledge et al., 2015). In ECs, the
major functional component of the adherent junction is VE-
cadherin. During transendothelial migration, there is a transient
gap in VE-cadherin at the site of the transmigrating leukocytes,
which facilitates transmigration (Dejana and Giampietro, 2012).
This gap has been shown to be triggered by constitutive
shedding of VE-cadherin by ADAM-10, which is promoted
by Tspan5 and Tspan17 and therefore allows T-cell diapedesis
(Reyat et al., 2017).
Transcellular leukocyte migration only occurs for a minority
of emigrating cells and mostly takes place in thin parts
of the endothelium (Carman and Springer, 2004). In this
route, leukocyte migration occurs through membrane-associated
channels, which act as a gateway for leukocytes through the body
of ECs. In fact, the preferred route of leukocyte transmigration
depends on the leukocyte type and also the type of vascular bed
(Dvorak and Feng, 2001). The endothelium is heterogeneous in
different vascular beds, depending on the size and the organ
considered (Aird, 2007). ECs in the arterioles of the vascular
system have lower permeability to leukocytes, whereas those in
the venules are thinner and permissive allowing leukocytes to
easily transmigrate particularly in postcapillary venules (Dejana
et al., 2009). In addition, the endothelial barrier can be even
more permissive such as in lymphoid organs (Miyasaka and
Tanaka, 2004), or very tight such as in the central nervous system
(Wolburg and Lippoldt, 2002).
To reach inflamed tissues, leukocytes need to migrate through
the basement membrane. The basement membrane is made
up of laminin and collagen type IV (Mutgan et al., 2020). In
murine models, leukocytes cross the basement membrane at areas
with low expression of laminin (Song et al., 2017). PECAM-
1, CD99, and CD99L2 are required for homophilic interactions
between leukocyte and ECs to initiate the migration through the
basement membrane (Thompson et al., 2001; Bixel et al., 2010;
Sullivan et al., 2016). Leukocytes express several membrane-type
matrix metalloproteinases (MMP) including the secreted- and
membrane-anchored MT-MMPs, which develop an appropriate
proteolytic reaction (Marco et al., 2013) and enable cells to
cross this structural barrier. However, the exact mechanisms still
remain to be fully characterized. Finally, following a successful
diapedesis, leukocytes utilize a chemokine gradient to migrate
toward the site of infection upon their entry into inflamed tissues
(Ley et al., 2007).
EXPRESSION OF ADHESION
MOLECULES IN T2DM
Cell adhesion molecules (CAMs) are glycoproteins expressed on
the surface of various cell types such as ECs and leukocytes
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(Galkina and Ley, 2007). Upon inflammation, vascular ECs
express or up-regulate the expression of CAMs that increase the
attachment of leukocytes to the endothelium (Cook-Mills et al.,
2011). Selectins, ICAM-1 and VCAM-1 are the major CAMs
responsible for leukocyte adhesion (Huo and Ley, 2001). Soluble
form of CAMs (sCAMs) in the circulation indirectly reflect the
rate of endothelial expression and activation of CAMs since they
are shed from the surface of ECs and lymphocytes after being
activated (Abe et al., 1998). Elevated expression and activity of
CAMs are therefore indicative of inflammation and endothelial
dysfunction (Cook-Mills et al., 2011).
Soluble CAMs and Selectins
The baseline levels of circulating E-selectin, ICAM-1, and
VCAM-1 were found higher in patients with T2DM compared
to healthy controls (Meigs et al., 2004). A study on 150 Japanese
patients with T2DM showed that higher serum concentrations
of sVCAM-1 and sE-selectin were positively correlated with
fasting plasma glucose levels, and negatively correlated with
insulin sensitivity (Matsumoto et al., 2002). Higher levels of
circulating CAMs in T2DM is linked to an increased production
of advanced glycosylation end products (AGEs) and oxidative
stress occurring under hyperglycemic conditions (Hadi and
Al Suwaidi, 2007). The interaction of AGEs with the vessel
wall components increases the generation of reactive oxygen
species, which results in an increase in the surface expression
of CAMs on activated ECs (Wen et al., 2002; Basta et al., 2004;
Farhangkhoee et al., 2006).
Hyperinsulinemia can also directly affect the surface
expression of adhesion molecules on ECs from healthy
volunteers and from patients with non-insulin-dependent
diabetes in vitro (Okouchi et al., 2002). Culture of ECs in insulin-
rich medium (over 50 microUnit/ml) for 24 h increased the
surface expression of PECAM-1 but not of ICAM-1, P-selectin
or E-selectin (Okouchi et al., 2002). This was clearly associated
with an increase in neutrophil adhesion therefore suggesting that
high insulin conditions promote vascular injury and therefore
T2DM-associated macro- and micro-vascular complications.
However, a recent study on 58 patients with T2DM on insulin
therapy and displaying microvascular complications found lower
levels of serum sICAM-1 in these patients irrespective of the type
of diabetic complication when compared to age-matched healthy
controls (Hocaoglu-Emre et al., 2017). Since the participants
with T2DM were also receiving angiotensin-converting enzyme
(ACE)-inhibitor agents, decreased levels of sICAM-1 might
have resulted from the combination of insulin and ACE-
inhibitor therapies. Indeed, both insulin and ACE inhibitors can
individually inhibit CAMs surface expression on ECs as well
as their circulating levels (Drexler et al., 1995; Aljada et al.,
2000). However much remain to be clarified in this area as
the effect of both insulin and ACE inhibitors seems to vary in
different patient cohorts. Some studies have hypothesized that
these discrepancies between cohorts are linked to the degree of
complications and the bigger impact seems to occur in late-stage
diabetic complications when other treatments such as ACE-
inhibitors are used. The conflicting evidence about the levels of
sCAMs in the circulation suggests that different CAMs may play
different roles in the different stages of vascular complications in
T2DM (Hocaoglu-Emre et al., 2017).
Surface Expression of CAMs on the
Endothelium
Variations in the expression of adhesion molecules on the
vasculature play a role in microangiopathy in patients with
T2DM by enhancing leukocyte adhesion in the vasculature and
causing capillary obstruction (McLeod et al., 1995). This has been
observed in different vascular beds and is linked to a majority
of complications such as diabetic nephropathy (Gu et al., 2013)
and retinopathy (McLeod et al., 1995). A study on 40 patients
with T2DM showed a significant increase in the expression of
ICAM-1 and VCAM-1 on vascular ECs from the conjunctiva in
comparison with conjunctiva from healthy controls (Khalfaoui
et al., 2008). Confocal microscopy imaging of retina vessels
in streptozotocin (STZ)-induced hyperglycemic mice reported
increased VCAM-1 protein levels after 8 weeks, and this
was synchronized with the expression of the inflammatory
cytokines TNFα, IL-6 and interleukin 1 beta (IL-1β) in the
retina (Gustavsson et al., 2010). However, not many studies have
performed in depth study of leukocyte recruitment in patients
and in mice models to show that defects in leukocyte recruitment
could mean leukocyte trafficking is impaired despite upregulation
of endothelial CAMs.
Vascular adhesion protein-1 (VAP-1) is an enzyme and an
adhesion molecule mainly expressed by ECs, smooth muscle,
and the adipose tissue (Kuo et al., 2019). Endothelial VAP-1
supports leukocyte rolling, firm adhesion, and transmigration
(Salmi and Jalkanen, 2019). The catalytic activity of VAP-1 can be
damaging and cytotoxic to ECs via the generation of AGEs, which
are involved in the pathogenesis of diabetic complications such
as retinopathy, nephropathy, neuropathy, and atherosclerosis
(Stolen et al., 2004).
Vascular adhesion protein-1 expressed on the vessels in the
pancreatic islet of Non-Obese Diabetic (NOD) mice (model
of T1DM) was associated with high degree of lymphocyte
infiltration into the islets (Bono et al., 1999). Invalidation of
the gene encoding VAP-1, using a null mutation in the amine
oxidase copper-containing-3 (AOC3), decreased infiltration of
T-cells, macrophages and NK cells in both epididymal and
inguinal white adipose tissue of AOC3-KO mice compared to
age-matched wild-type controls. This reduction in leukocyte
infiltration was associated to a reduced capacity of leukocyte
extravasation normally enabled via VAP-1 (Jargaud et al., 2020).
Serum VAP-1 levels are higher in patients with T2DM and
in patients with chronic kidney disease, which makes serum
VAP-1, a good predictor of end-stage renal disease in diabetic
patients and a useful biomarker to improve risk stratification
of patients with T2DM (Li et al., 2016). Many in vivo studies
further validate the role of VAP-1 as an anti-inflammatory target
(Xu et al., 2006; Foot et al., 2013; Carpéné et al., 2019). Indeed,
administration of a long-lasting VAP-1 and 2 inhibitor, PXS-
4681A, in a mouse model of LPS-induced lung inflammation
attenuated neutrophil migration into the lungs (Foot et al.,
2013). PXS-4681A is a promising drug candidate as it ensures
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complete and long-lasting inhibition of the enzymes after a single
low dose in vivo and could also be tested in other models of
chronic inflammation.
Surface Expression of CAMs on
Leukocytes
Leukocyte adhesion to the endothelium is mediated by surface
integrins expressed on leukocytes such as macrophage integrin-
1 (Mac-1) or CD11b/CD18, also known as αMβ2 (Carlos and
Harlan, 1994). In a study comparing patients with T2DM to
age-matched healthy controls, basal expression of CD11b on
monocytes and neutrophils did not differ between the groups
(Sampson et al., 2002). However, higher expression of CD11b
was observed on monocytes after a glucose load in both T2DM
and control groups. This suggests, an association between
hyperglycemia and monocyte-endothelial interactions through
increased expression of monocytic CD11b (Sampson et al., 2002).
Higher expression of CD11b in both diabetic and control groups
after a glucose load could be due to the translocation of stored
CD11b to the cell surface in response to any acute or sudden
change in glucose levels regardless of basal plasma glucose
(Sampson et al., 2002). However, another group later found
higher monocyte expression of CD11b at baseline in patients
with obesity, which may suggest higher degree of leukocyte
activation with increased adhesive properties in this group
compared to lean participants (Van Oostrom et al., 2004). This
was not limited to monocytes as later de Vries et al. (2015) also
found up-regulation of CD66b (glycosylated antigen implicated
in adhesion to E-selectin) on neutrophils from patients with
T2DM. Change in CD66 can be implicated in aberrant neutrophil
recruitment to the vasculature but also indicates neutrophil
activation and degranulation (Weber, 2003), which confirms how
hyperglycemia can lead to exacerbated inflammatory responses.
Dipeptidyl peptidase-4 (DPP-4) or CD26 is an amino-
peptidase expressed in numerous tissues including the
vasculature and in immune cells (Mentlein, 1999; Lambeir
et al., 2003). DPP-4 cleaves dipeptides from the N-terminus of
many chemokines and cytokines, usually after a penultimate
proline or an alanine (Broxmeyer et al., 2016). DPP-4 controls
glucose homeostasis through regulating bioactivity of the incretin
hormone and glucagon-like peptide 1 (Augustyns et al., 2010).
Involvement of DPP-4 in metabolic control raises the possibility
that it may play a role in metabolic diseases such as diabetes and
obesity (Mulvihill and Drucker, 2014; Omar and Ahrén, 2014).
Given its various roles and its altered expression and activity,
DPP-4 has been implicated in several pathological processes,
including inflammation, viral entry and immune-mediated
diseases (Lambeir et al., 2003; Yu et al., 2010).
Plasma levels of DPP-4 and circulating DPP-4 activity both
increase with obesity and this correlates with insulin resistance
(Mulvihill and Drucker, 2014; Ahmed et al., 2017). Numerous
studies have detailed the effects of DPP-4 inhibitors on insulin
and/or glucagon secretion, but little evidence indicates that
DPP-4 inhibitors directly improve chronic inflammation. The
effects of DPP-4 inhibition was investigated in diet-induced
adipose tissue inflammation using (Gck+/2) diabetic mice, an
animal model of non-obese T2DM (Shirakawa et al., 2011).
DPP-4 inhibition in this model led to a significant reduction in
adipose tissue infiltration of CD8+ T-cells and M1 macrophages
which was associated to decreased mRNA expression levels of
TNF-α and MCP-1 in the adipose tissue (Shirakawa et al.,
2011). Because DPP-4 mediates the cleavage of many chemokines
and adipokines, inhibition of DPP-4 may cause off-target
side effects and further research is needed to clarify this
(Shirakawa et al., 2011).
In addition, Zhuge et al. (2016) found that the expression
of DPP-4 was mainly detected and up-regulated on F4/80+
macrophages in the white adipose tissue of HFD-induced obese
mice). Oral administration of the DPP-4 inhibitor, linagliptin,
caused an anti-inflammatory macrophage polarization with a
dynamic M2 shift of macrophages within the adipose tissue
of HFD-induced obese mice compared to non-treated obese
mice, and this contributed to the attenuation of whole-body
insulin resistance (Zhuge et al., 2016). In this study, the anti-
inflammatory effects of DPP-4 inhibition were due to a decreased
in ROS generation and an attenuation of oxidative stress in the
white adipose tissue (Zhuge et al., 2016). Loss of macrophage
inflammatory protein-1α (MIP-1α), a chemokine and potential
DPP-4 substrate, abrogated the M2 macrophage-polarizing and
insulin-sensitizing effects of linagliptin in MIP-1α−/− mice on
HFD. This suggests that MIP-1α may be a substrate for DPP-4
and contributes to the regulation of macrophage polarization in
obesity models (Zhuge et al., 2016).
Altogether the in vivo studies highlight a potential role of
DPP-4 in the modulation of leukocyte migration by affecting
chemokines. However, this has not been extensively investigated
in the studies presented here as not all studies seem to have
linked this to migration despite the important role of DPP-4 at
inhibiting chemokines. The approved DPP4 inhibitors being used
in clinic, such as sitagliptin and vildagliptin are based on the
ability of DPP4 to lower glucose rather than its regulatory effects
on inflammation (Deacon, 2018).
Similar to studies investigating endothelial expression of
adhesion molecules in T2DM, data showing changes in adhesion
molecules/integrins on leukocytes have not performed analysis of
leukocyte recruitment in targeted tissues, instead this has been
extrapolated from knowledge on adhesion molecule profiles and
function in “normal” inflammatory responses, in other models
and/or diseases.
EXPRESSION OF CHEMOKINES AND
CHEMOKINE RECEPTORS IN T2DM
Chemokines and their receptors play a central role in leukocyte
trafficking and are involved in the pathophysiology of T2DM
(Buraczynska et al., 2012). Production and release of cytokines
and chemokines including CC-chemokine ligand 2 (CCL2),
CCL3 and CXC-chemokine ligand 8 (CXCL8) is increased
in the adipose tissue and pancreatic islets of patients with
T2DM (Donath and Shoelson, 2011; Xu et al., 2015). This
is associated with an increased recruitment of macrophages
in these tissues, and thus contributes to tissue inflammation
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(Donath and Shoelson, 2011; Xu et al., 2015). CCL2 (also known
as MCP-1) is known to regulate monocyte recruitment by
directing monocytes migration from the bone marrow to
inflamed tissues (Crane et al., 2009; Boels et al., 2017). The
CCL2-CCR2 axis has a key role in diabetes-related complications
such as retinopathy, nephropathy and neuropathy (White et al.,
2009; Zhu et al., 2014; Moreno et al., 2018; Monickaraj et al.,
2020). Indeed, contribution of CCL2-CCR2 axis to leukocytes
recruitment into the injured nerve was shown using a preclinical
model of peripheral neuropathic pain induced by chronic nerve
constriction (CCI) in Sprague–Dawley rats (Van Steenwinckel
et al., 2015). This study shows that CCl-induced mechanical
hypersensitivity in rats upregulated the expression of CCL2
and increased local macrophage infiltration in the sciatic nerve
compared to the sham group (Van Steenwinckel et al., 2015).
In contrast, in the same study, CCL2-deficient mice presented
attenuated CCI-induced mechanical hypersensitivity as well
as decreased number of macrophages infiltrating the injured
sciatic nerve. Altogether, these findings suggest that CCL2
could play an important role in mediating neuropathic pain by
increasing leukocyte infiltration in nerves but also by mediating
neuro-immune interactions during inflammation-induced pain
(reviewed in White et al., 2009).
In addition, upregulation of the CCL2 gene was also
demonstrated in retinas of STZ-induced diabetic rats, and
this was coincident with the trafficking and infiltration of
numerous monocytes into the retina (Rangasamy et al., 2014).
Furthermore, using CCL2 knockout (Ccl2−/−) mice, the same
authors found significantly decreased monocyte/macrophage
trafficking into diabetic Ccl2−/− retinas, indicating that this
chemokine may be essential for the alteration of the blood-
retinal barrier (Rangasamy et al., 2014). The role of CCL2-CCR2
axis is also widely investigated in diabetic renal injuries. Indeed,
accumulation of macrophages in the kidney was reduced in Ccl2
−/− db/db double knock-out diabetic mice compared to Ccl2
+/+ db/db animals (Chow et al., 2007). Immunohistochemistry
results from kidney biopsies of patients with T2DM showed
overexpression of CCL2 and CCR2 in the glomeruli of these
patients compare to healthy kidneys (Tarabra et al., 2009).
This was accompanied with reduced nephrin expression in
cultured podocytes from T2DM patients (Tarabra et al., 2009).
Moreover, in the STZ- model of diabetes, induction of diabetes
increased albuminuria in CCL2+/+ mice, which was significantly
reduced in CCL2-deficient mice. Together these studies suggest
a pathogenic role of the CCL2/CCR2 axis in the development
of diabetic nephropathy (Tarabra et al., 2009) and targeting
this pathway could be a potential therapeutic avenue to
reduce common diabetic complications associated with aberrant
infiltration of leukocytes.
Other chemokines and their receptors are also changed in
T2DM. CX3CL1 was found at higher levels in the subcutaneous
adipose tissue of patients with T2DM and in obese people
when compared to patients with normal weight and also was
shown to modulate monocyte adhesion to adipocytes (Shah et al.,
2011). CCL5 (RANTES) was also found at higher levels in the
circulation of 236 patients with T2DM, 242 individuals with
impaired glucose tolerance (IGT) but not in 244 individuals
with normal glycemic control (Herder et al., 2005). However,
higher circulating levels of CCL5 were not significantly associated
with other inflammatory variables and metabolic parameters,
suggesting more studies are required to evaluate the novel
hypothesis that CCL5 is a risk factor for T2DM.
Infiltration of inflammatory leukocytes in adipose tissue plays
an important role in the development of insulin resistance.
The inflammatory cytokines secreted by these cells interfere
with insulin signaling and decrease glucose uptake in peripheral
tissues (Asghar and Sheikh, 2017). Studies looking at ways
to down-regulate aberrant recruitment of leukocytes as a
mean to control inflammation and therefore restore insulin
sensitivity have targeted chemokine receptors such as CCR5 and
CCR2. CCR5 a chemokine receptor expressed by T-cells and
macrophages, plays a critical role in recruitment and polarization
of macrophage in inflammation. Kitade et al. (2012) showed that
a higher gene expression of CCR5 in the white adipose tissue
of High Fat Diet (HFD)-induced obese mice was concomitant
to an accumulation of macrophages in this tissue. Importantly,
mice deficient for CCR5 in their myeloid lineage did not develop
insulin resistance and diabetes normally induced by HFD. Loss
of CCR5 was associated with a reduction in total adipose
tissue macrophage content and polarization of macrophages
toward and an anti-inflammatory M2-dominant phenotype in
the adipose tissue (Kitade et al., 2012).
The administration of a dual CCR2/CCR5 antagonist has
shown to improve obesity-associated insulin resistance and
glucose intolerance via reducing macrophages and CD8+ T-cell
numbers in the white adipose tissue of HFD-fed mice, indicating
that blocking both CCR2 and CCR5 has potential to maintain
both metabolic and immune homeostasis in obesity-induced
inflammation (Huh et al., 2018).
Overall, these studies clearly demonstrate how up-regulation
of chemokine pathways, which in turn leads to aberrant
recruitment of leukocytes in different tissues is contributing to
some of the common diabetic complications and targeting this
pathophysiological process could be a promising therapeutic
advance. However, further research is required to fully
characterize the interactions and redundancy of chemokine
with chemokine receptors in T2DM.
INNATE AND ADAPTIVE IMMUNE CELL
IN T2DM
In this section, we will explore how the recruitment of innate
and adaptive immune cells changes in obesity and T2DM as
summarized in Table 1. Obesity-induced inflammatory events
originating from the adipose tissue such as production of local
inflammatory molecules are responsible for the activation of
immune responses and progression of systemic inflammation in
patients with T2DM (Richardson et al., 2013).
Innate Immune Cells
Monocytes and Macrophages
Innate immune cells play a critical role in the early stage of
adipose tissue inflammation in T2DM (Weisberg et al., 2003).
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TABLE 1 | A summary of studies discussed in this review assessing obesity/T2DM-related changes to the trafficking of innate and adaptive immune cells.
Effect of obesity/T2DM on cell recruitment Potential mechanisms References
Monocyte/ macrophage ↑ recruitment of macrophages in retinas of
STZ-induced diabetic rats
CCL2-CCR2 axis Rangasamy et al., 2014
↑ recruitment of macrophages in kidney of
STZ-induced diabetic mice
CCL2-CCR2 axis Tarabra et al., 2009
↑ adhesion of monocyte to adipocytes in the
subcutaneous adipose tissue of patients with
T2DM and obesity (Human study)
↑ CX3CL1 expression in adipose tissue Shah et al., 2011
↑ recruitment of macrophages in white adipose tissue
of HFD-induced obese mice
↑ CCR5 expression in white adipose tissue Kitade et al., 2012
↑ levels of F4/80 and CD11c mRNA expression in
adipose tissue of HFD fed mice
↑ Adipose tissue expression of ICAM-1, VCAM-1,
CCL2, CXCL14
Kawanishi et al., 2010
↑ expression of F4/80 in adipose tissue of HFD fed
mice
↑ Adipose tissue expression of mRNA for ICAM-1 Brake et al., 2006
↓ RPMs in db/db mice
↑ Increased M2 polarization
Ongoing chronic inflammation in the peritoneal
cavity in db/db mice
Liu et al., 2012
In vitro ↓ adhesion and phagocytosis capacity of
RPMs from in db/db mice
abnormal microenvironment in db/db mouse Liu et al., 2012)
↓ monocyte/macrophages in lung tissue of diabetic
DPP4H/M mice following infection by MERS-CoV
↓ lung tissue expression of Ccl2 and Cxcl10 Kulcsar et al., 2019
DCs ↑ CD11chighF4/80low DCs in mice visceral adipose
tissue in HFD-induced obese mice
Not described Bertola et al., 2012.
↑ CD11c+CD1c+ cDCs in obese human
subcutaneous adipose tissue (Human study)
Not described Bertola et al., 2012.
↑ CD11c+ cDCs numbers in the adipose tissue of
HFD-fed mice
Not described Chen et al., 2014
Neutrophils ↑ trafficking of neutrophil into mice visceral adipose
tissue after 3 days on HFD
↑ CD11b surface expression on neutrophils Elgazar-Carmon et al.,
2008
↑ recruitment of neutrophils into the adipose tissue of
HFD-fed mice after 3 days on HFD (sustained
infiltration for up to 90 days on HFD)
↑ expression and activity of neutrophil-secreted
elastase in the adipose tissue of HFD-fed mice
Talukdar et al., 2012
CD8+ T-cells ↑ infiltrated CD8+ effector T-cells in visceral adipose
tissue in HFD-fed mice
Activation of CD8+T cells by endogenous stimuli
localized in the adipose tissue
Nishimura et al., 2009.
↓ lower numbers of CD8+ T-cells in their brains in
db/db mice following infection with West Nile virus
↓ expression of E-selectin and ICAM-1 in db/db
brains
Kumar et al., 2014
CD4+ T-cells ↓ CD4 + T-cells in lung tissue of diabetic DPP4H/M
mice following infection by MERS-CoV
↓ lung tissue expression of Ccl2 and Cxcl10 Kulcsar et al., 2019
Tregs ↓ regulatory T-cells in visceral adipose tissue of
HFD-fed mice
Not described Nishimura et al., 2009.
↓ CD4+ Tregs HFD-fed mice ↓ levels of adiponectin in obese fat Feuerer et al., 2009;
Ilan et al., 2010.
B-cells ↑ number of B-cells in the bone marrow of HFD-fed
mice
Not described Trottier et al., 2012
↓ number of B-cells in the bone marrow of HFD-fed
mice
lower expression of Pax5 in the bone marrow of
HFD-fed mice
Chan et al., 2012
Granulocytes ↓ granulocytes in the alveolar airspace of stz-induced
diabetic mice following infection by Klebsiella
pneumoniae
↓ levels of (CXCL1, CXCL2) and (IL-1β, TNFα) in lung
tissue
Martinez et al., 2016
Monocytes derived from the bone marrow remain in the
circulatory system for 1–2 days before they migrate into
peripheral tissues, where they turn into fully mature resident
macrophages (Martinez-Pomares et al., 2003) either with a
M1 pro-inflammatory or M2 anti-inflammatory phenotype in
response to local factors (Mosser, 2003). In a recent in vivo
study, an acute decrease in number of circulating monocytes
was synchronized with a concomitant infiltration of macrophages
into visceral adipose tissue, therefore demonstrating dynamic
changes in blood monocyte trafficking at the early stages of
HFD-induced diabetes (Liu et al., 2020). Higher levels of F4/80
and CD11c mRNA expression in adipose tissue of HFD fed
mice, representative of a M1 polarization, were attributed to
an elevated gene expression of ICAM-1, VCAM-1, CCL2 and
CXCL14 in this tissue, which facilitates macrophage trafficking
(Kawanishi et al., 2010). Similarly, Brake et al., found higher
levels of mRNA for ICAM-1 in mice on a 3-week HFD, as
well as an increased expression of F4/80 in their adipose tissue
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(Brake et al., 2006). The activation of M1 macrophages is
associated with release of pro-inflammatory mediators, such
as TNFα and IL-6 (Biswas and Mantovani, 2010). Using an
HFD-induced rat model of T2DM, Shanaki et al. reported
increased serum and adipose tissue levels of IL-6 and TNFα in
T2DM rats compared to control animals. This pro-inflammatory
shift was linked to higher fasting plasma glucose levels and
insulin resistance in the diabetic animals (Shanaki et al.,
2020). The impact of long-term diabetes on the functions
of macrophages was investigated using a 5-month old db/db
mice model of T2DM (Liu et al., 2012). In this study, the
authors focused on resident peritoneal macrophages (RPMs) to
investigate potential changes of their function, phenotype and
migratory capacity. RPMs numbers were reduced in db/db mice
compared to C57BL/6 control mice and most were preferentially
polarized toward a M2 phenotype. Since M2 macrophages exhibit
immunosuppressive functions and therefore contribute to the
resolution of harmful inflammation, their increased proportion
in the db/db mice may be caused by an effort to control the
chronic low-grade inflammation observed in the peritoneal cavity
of these mice (Liu et al., 2012). Furthermore, in this study,
in vitro assessment of db/db RPMs highlighted their decreased
adhesion capacity along with a decreased phagocytosis ability
compared to wild-type RPMs. These observations validate that
diabetes and obesity are associated with immune dysfunction
which predispose these patients to an increased susceptibility to
infections (Liu et al., 2012).
Human studies also indicate a role of macrophages in
mediating insulin resistance. Indeed, higher numbers of
circulating leukocytes are found in patients with T2DM along
with higher Free Fatty Acid (FFA) and IL-6 circulating levels
(van Beek et al., 2014). Elevated number of total leukocytes
counts in patients with T2DM was also characterized in other
studies (Kizilgul et al., 2018; Palella et al., 2020) and were often
indicative of macro- and micro-vascular complications and
diabetes duration (Papazafiropoulou et al., 2010; Moradi et al.,
2012). In particular, Wouters et al. demonstrated higher numbers
of circulating classical monocytes and this was associated with
higher presence of M1 macrophages in the white adipose
tissue of individuals with obesity compared to individuals with
normal weight (Wouters et al., 2017). In addition, impaired
glucose tolerance was associated with the presence of crown-like
structures (marker of adipose inflammation) in the adipose tissue
of patients with obesity and T2DM compare to patients with
obesity and normal glucose tolerance (van Beek et al., 2014).
Most of the current observations seem to indicate a crucial
role of macrophage infiltration in the adipose tissue of patients
with obesity and T2DM. However, it is not entirely clear what
mechanisms mediate recruitment of macrophages in these tissues
and more research is needed to understand whether macrophage
infiltration could be limited to improve insulin sensitivity and
glucose tolerance and therefore prevent diabetic complications.
Neutrophils
Neutrophils are the most abundant subsets of leukocytes of
the innate immune system in humans and are the first to
infiltrate inflamed tissue and promote subsequent recruitment
of other leukocytes such as monocytes (Soehnlein et al., 2008).
The number of circulating neutrophils in patients with T2DM
increases in comparison to age- and gender-matched healthy
controls (Huang et al., 2019). However, neutrophils isolated from
patients with T2DM displayed normal migratory capacity and
phagocytic rate (Huang et al., 2019). Neutrophil trafficking into
murine visceral adipose tissue was reported after 3 days on HFD.
The same study reported an absence of neutrophils in the adipose
tissue after 7 days on HFD and that neutrophil adhesion to mouse
adipocytes depends on their activation state (Elgazar-Carmon
et al., 2008). Here, the degree of CD11b surface expression on
neutrophils correlated with their capacity to adhere. However,
the mechanisms responsible for the absence of neutrophils in the
adipose tissue after 7 days on HFD was not explained in this study
(Elgazar-Carmon et al., 2008). Similarly, Talukdar et al. (2012)
found an early recruitment of neutrophils into the adipose tissue
of HFD-fed mice after 3 days. Here, the time course of neutrophil
infiltration into the adipose tissue showed a sustained infiltration
in the adipose tissue for up to 90 days on HFD (Talukdar et al.,
2012). According to this study, the trafficking of neutrophils was
associated with an elevated expression and activity of neutrophil-
secreted elastase in the adipose tissue of HFD-fed mice which
increased after only 3 days of HFD and remained high after
12 weeks. Elastase is a neutrophil-specific protease which can
promote inflammatory responses (Pham, 2006) and inhibition
of neutrophil elastase in HFD-induced obese mice improved
glucose tolerance and reduced trafficking of neutrophils into the
adipose tissue (Talukdar et al., 2012).
Dendritic Cells
Dendritic cells (DCs) are antigen-presenting immune cells
that mediate lymphocytes polarization into effector cells (Yu
and Martin-Gayo, 2019). In humans, two major subtypes of
DCs are identified according to their markers expression:
conventional or myeloid DCs (cDCs) (CD11c+ CD1c+ CD141+)
and plasmacytoid DCs (pDCs) (CD11c− CD123+) (Tamura
et al., 2005; Gilliet et al., 2008; Sundara Rajan and Longhi,
2016). In mice, two major DC subsets have also been described:
CD11clowB220+ (pDCs) and CD11chighB220− cells that include
cDCs (O’Keeffe et al., 2002). The number of circulating
cDCs increases in obese post-menopausal women with T2DM
compared to age-matched healthy women and a smaller increase
was observed for pDCs (Musilli et al., 2011). This change
in DCs numbers in the circulation suggests that DCs might
contribute to pathological vascular remodeling (Musilli et al.,
2011). Mráz et al. reported a decrease in the number of total
DCs in the subcutaneous adipose tissue from patients with
T2DM compared to non-diabetic individuals. In contrast, the
number of pDCs was increased in the subcutaneous adipose
tissue of the T2DM group. These differences suggest a potential
role of pDCs in the development of T2DM-associated adipose
tissue low-grade inflammation (Mráz et al., 2019). Bertola et al.
investigated the role of DCs in the regulation of adipose tissue
inflammation in a murine HFD-induced obesity model and
in two cohorts of obese subjects (Bertola et al., 2012). The
authors in this study only found CD11chighB220− DCs in
the visceral adipose tissue of lean mice. In contrast, obesity
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was associated with the presence of CD11chighF4/80low DCs
in murine visceral adipose tissue, and CD11c+CD1c+ cDCs
in human subcutaneous adipose tissue (Bertola et al., 2012).
CD11chighB220− DCs resident in the adipose tissue of lean
mice participate in the differentiation of naive CD4+ T-cells
into effector T-cells with a predominance of Th1 cells over
Th17 cells. In contrast, the adipose tissue of HFD-induced
insulin resistant mice displayed a switch from Th1 towards
a Th17 phenotype (Bertola et al., 2012). In addition, the
presence of CD11c+CD1c+ cDCs in the subcutaneous adipose
tissue of obese subjects correlated with CD1c expression and
a concomitant skew towards a Th17 T-cell phenotype. Finally,
CD1c expression strongly correlated with insulin resistance in
patients with a high Body Mass Index (BMI) (Bertola et al.,
2012). Altogether, these observations suggests an important
role of inflammatory DCs in obese and diabetic adipose
tissue inflammation by switching T-cell responses toward Th17
responses, which is associated with insulin resistance (Bertola
et al., 2012). These observations were confirmed by another
group who showed that CD11c+ cDCs infiltrated the adipose
tissue of HFD-fed mice and also secrete high levels of IL-6
and IL-23, which promoted a Th17 T-cell phenotype (Chen
et al., 2014). The presence of DCs in the visceral adipose
tissue of HFD-mice can also induce the formation of crown-
like structures which enclose macrophages and were linked to
adipose tissue inflammation and insulin resistance (Stefanovic-
Racic et al., 2012). Depletion of DCs results in loss of adipose
tissue macrophage infiltration, and this could be restored by
DC replacement in DC-null mice (Stefanovic-Racic et al., 2012).
All together, these studies show the importance of DCs in
determining the immune phenotype of lean versus obese or
diabetic adipose tissue.
Adaptive Immune Cells
The mucosal immune system is a compartment of the
adaptive immune system which is located near the surface,
where most pathogens invade, providing the first line of
defense (Janeway et al., 2001). The gut microbiota is key
to the development and modulation of mucosal immune
responses and maintains perfect balance between commensal
flora and pathogens, as well as the microbiota and the
immune system (Wang and Li, 2015). The alteration of such
balance is called dysbiosis (Pagliari et al., 2018). Given that
the pancreas does not have its own microbial collection,
the gut microbiota may be involved in the pathogenesis of
pancreatic disorders such as pancreatitis (Signoretti et al.,
2017). Recently, Guo et al. (2017) demonstrated that HFD
was able to alter gut microbial communities and increase
circulating pro-inflammatory cytokines, such as TNFα, IL-6
and IL-1β. In addition, recent evidence demonstrated that
intestinal dysbiosis may also cause alterations in the Th17
cells/Tregs balance which are responsible for the development
inflammatory disease including obesity-related T2DM (Luo
et al., 2017).Thus, understanding the mechanisms responsible
for this alteration will allow to develop novel translational
therapeutic targets to potentially treat these inflammatory
diseases (Pagliari et al., 2018). In this section, we mostly focus
on T- and B-cells as very little is known on mucosa-associated
homing mechanisms in the context of T2DM.
T-Cells
Although, earlier studies focused on the role of innate immunity
(macrophages) as the major cause of chronic low-grade
inflammation in T2DM, the adaptive immune system also plays
a role in progression of T2DM (Zhou et al., 2018). Evidence
shows that B-cells are the first to infiltrate the adipose tissue
of mice on HFD, quickly followed by T-cells and finally an
accumulation of macrophages leading to insulin resistance, but
no changes in resident macrophages populations (Duffaut et al.,
2009). Nishimura et al. (2009) found larger number of infiltrated
CD8+ effector T-cells along with reduced numbers of CD4+
helper and regulatory T-cells in visceral adipose tissue of HFD
fed mice). In these conditions, a majority of CD8+ T-cells
infiltrate the adipose tissue thereby promoting recruitment and
activation of macrophages. This sequential accumulation of
leukocytes is clearly linked with glucose intolerance and a
decrease in insulin sensitivity in wild-type animals (Duffaut et al.,
2009). Studies in the lymphocyte-deficient RAG2−/− knockout
mouse provide strong evidence for the role of lymphocytes
in HFD-mediated adipose tissue inflammation. Unexpectedly,
lymphocyte-deficient animals displayed striking accumulation
of macrophages and NK cells in the adipose tissue compared
to wild-type mice (Duffaut et al., 2009). This accumulation of
NK cells highlights an overreaction of the innate immunity in
absence of the adaptive immune system. Indeed, NK cells have
potent cytotoxic effector functions and produce chemokines and
cytokines that can recruit macrophages (Duffaut et al., 2009). The
exaggerated recruitment of macrophages in lymphocyte-deficient
mice demonstrates that early lymphocyte infiltration could
be considered a protective process to decrease adipose tissue
inflammation and suggests adipose tissue as a site of dynamic
innate and adaptive immune system during diet-induced obesity
and insulin resistance (Duffaut et al., 2009).
According to recent reports, the changes in quantity and
polarization of adipose tissue T-cells during weight gain is a
key regulator of systemic insulin sensitivity (Deng et al., 2017).
HFD is associated with increased numbers of Th1 CD4+ T-cells
and decreased numbers of CD4+ Tregs in the adipose tissue
(Feuerer et al., 2009; Ilan et al., 2010). The depletion of Tregs
using diphtheria toxin in mice leads to an induction of genes
encoding inflammatory cytokines such as TNFα and IL-6 in
visceral adipose tissue and enhance levels of fasting insulin
(Feuerer et al., 2009). On the other hand, in the same study,
increasing the quantity Tregs in the adipose tissue using a Tregs–
enriched HFD-fed mice model, improved insulin resistance and
glucose tolerance (Feuerer et al., 2009). Since, the gene expression
of IL-10 was increased in the adipose tissue of Tregs–enriched
animals, the metabolic changes observed can be attributed to IL-
10 synthesis by Tregs in the adipose tissue of these mice (Feuerer
et al., 2009). These findings suggest a strong therapeutic potential
for Tregs to suppress inflammation and improve insulin action
in obesity and T2DM. It is therefore key to understand how
Tregs migratory capacity and infiltration in the adipose tissue
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could be manipulated in patients. In addition, further studies are
required to fully characterize the involvement of different T-cell
subsets and characterize the intricate balance between innate and
adaptive immune regulations.
B-Cells
B-cells have been shown to play important roles in many chronic
inflammatory and autoimmune conditions (Yanaba et al., 2008;
Mariño and Grey, 2012) but only recently has their role been
revealed in obesity-associated insulin resistance. B-cells infiltrate
the white adipose tissue in diet-induced obesity models and
contribute to insulin resistance (Winer et al., 2011). The data on
the development of B-cells in the bone marrow of obese models
is controversial. Indeed, B-cells numbers in the bone marrow of
mice on HFD were significantly increased after 90 days (Trottier
et al., 2012). However, number of B-cells in the bone marrow
were reduced in C57BL/6 mice on HFD for 210 days in another
study (Chan et al., 2012). This reduction was associated to a
lower expression of Pax5 in the bone marrow of HFD-fed mice
(Chan et al., 2012). Differences between these studies may be due
the type and duration of HFD. B-cell infiltration in the white
adipose tissue of C57BL/6 mice peaks at around 3–4 weeks of
HFD (Duffaut et al., 2009). The importance of B-cells in adipose
tissue inflammation has been studied in vivo using B-cell null
mice (µMT mice). Attenuated inflammation in visceral adipose
tissue of µMT mice was shown by a reduced infiltration of
macrophages. In this study, following 15 weeks of HFD, serum
glucose levels were unchanged in obese µMT mice while fasting
glucose levels increased in the control wild-type group (DeFuria
et al., 2013). These data support the conclusion that B-cells
regulate macrophage infiltration into the adipose tissue during
inflammation and this contributes to insulin resistance.
IMMUNE RESPONSE FOLLOWING
INFLAMMATORY STIMULUS IN T2DM
Hyperglycemia in diabetes can impair immune response to
pathogens such as, fungi, bacterial and viral infections (Hostetter,
1990; Javid et al., 2016; Kulcsar et al., 2019). As a result, patients
with diabetes are more susceptible to infections (Berbudi et al.,
2020). Although the plasma concentration of sCAMs tends to
be generally higher in patients with T2DM compared to healthy
controls, their expression is differently affected in response to
inflammatory pathogens in patients with T2DM. Indeed, plasma
levels of sE-selectin, sVCAM-1 and sICAM-1 after intravenous
injection of E.coli lipopolysaccharide (LPS) were lower in patients
with T2DM compared to healthy volunteers. This study revealed
that patients responded with an attenuated up-regulation of
sCAMs even though the basal plasma concentration of these
adhesion molecules were generally higher in diabetic individuals
compared to healthy controls (Andreasen et al., 2010). Also,
in this study, T2DM was associated with less pronounced
LPS-induced cytokine responses. This weaker cytokine response
following inflammatory stimuli in T2DM is also shown in vitro
with cultures of peripheral blood mononuclear cells (PBMCs).
Stimulation of PBMC from patients with diabetes with LPS
and Burkholderia pseudomallei lead to a lower production
of IL-1β and IFNγ respectively, compared to PBMCs from
healthy donors (Mooradian et al., 1991; Tan et al., 2012). All
together these findings may explain the immune dysfunction and
increased risk of infections associated with T2DM (Andreasen
et al., 2010). However, the evidence demonstrating changes in
leukocyte recruitment following pathogen invasion in T2DM
is rare and mostly limited to animal experimental studies.
Accordingly, db/db mice infected with West Nile virus, had
lower numbers of CD45+ leukocytes and CD8+ T-cells in their
brains compared to wild-type mice (Kumar et al., 2014). Effector
CD8+ T-cells are necessary to limit viral load and therefore a
lack of CD8+ T-cells infiltration, which may be caused by a
decreased migratory capacity or changes in the brain vasculature,
lead to an increased viral burden in the brain of infected mice
(Shrestha and Diamond, 2004; Kumar et al., 2014). This defect in
leukocyte recruitment was in fact due to a reduced expression of
E-selectin and ICAM-1 in db/db brains which failed to properly
support the CD8+ T-cells adhesion and migration (Kumar
et al., 2014). Furthermore, impaired recruitment of leukocytes
is not only due to changes on leukocytes themselves and in
the local environment but can also be attributed to attenuated
cytokine and chemokine production in diabetic mice. In STZ-
diabetic mice infected by Klebsiella pneumoniae, which causes
pneumonia (Bengoechea and Sa Pessoa, 2019) lower numbers
of granulocytes were found in the alveolar airspace along with
attenuated chemokines (CXCL1, CXCL2) and cytokines (IL-1β,
TNFα) levels in lung tissue when compared to control mice
(Martinez et al., 2016). Moreover, a recent study investigated the
impact of T2DM on respiratory infection caused by Middle East
respiratory syndrome coronavirus (MERS-CoV) (Kulcsar et al.,
2019). In this study, humanized DDP4 mice were susceptible
to MERS-CoV and T2DM was induced by HFD (Kulcsar
et al., 2019). Following infection with MERS-CoV, diabetic
DPP4H/M mice displayed weight loss and had a longer phase of
severe disease with delayed recovery. Importantly, lung tissue
analysis in the diabetic mice showed a decreased number of
macrophages, CD4+ T-cells, and lower expression of TNFα and
IL-6 in the HFD group, compared to control DPP4H/M mice
following infection (Kulcsar et al., 2019). These results suggest
that MERS-CoV infection in patients with T2DM diabetes may
develop more severe disease as a result of a dysregulated immune
response targeting not only migratory capacities of leukocytes
but the local environment by modulating secreted factors and
expression of adhesion molecules. Maximal endothelial cell
adhesion molecule expression or chemokine/cytokine receptor
downregulation/internalization in chronic inflammatory
conditions could theoretically cause an impaired immune
response to an infection. In addition to alternative mechanisms,
it is also plausible that insulin could have agonist and antagonist
effects on the same signaling pathway based on its concentration
and receptor expression state (i.e., the "U-shaped" biologic
dose-response curve) (Calabrese and Baldwin, 2001). In general,
it seems that high glucose levels are associated with impaired
expression of adhesion molecules, cytokines and the chemokines
supporting efficient leukocyte migration during an inflammatory
response to infections in T2DM conditions. This is in contrast
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with studies mentioned above which show how basal expression
of adhesion molecules and chemokines/chemokine receptors is
increased in different vascular beds and leukocytes in T2DM
conditions. The defect in cytokine response to pathogen in
T2DM is partially related to insulin deficiency and recently has
been discussed by Tessaro and Martins (Tessaro et al., 2017).
In their study, insulin increased TNFα and IL-6 release by bone
marrow-derived macrophages from diabetic C57BL/6 mice
following LPS stimulation. This finding supports the idea that
insulin is crucial to induce a proper immune reaction in response
to inflammatory stimuli. However, in the same study insulin
inhibited LPS-induced pro-inflammatory cytokine secretion by
peritoneal macrophages from diabetic mice (Tessaro et al., 2017).
Together findings suggest that beyond its glucose modulatory
effects, insulin also has distinctly immunomodulatory effects in
macrophages and these urgently require to be fully understood.
THERAPEUTIC TARGETING OF
LEUKOCYTE TRAFFICKING IN T2DM
Given that T2DM is a chronic inflammatory disorder,
characterizing and targeting possible inflammatory pathways
could be efficient to prevent and control diabetes and its
vascular complications.
Chemokine and Cytokine Inhibition
Chemokine and cytokine pathways are known to govern the
trafficking of leukocytes into peripheral tissues (Yao et al., 2014).
Potential antagonists targeting chemokine receptors and drugs
blocking inflammatory cytokines have been developed and tested
in many inflammatory conditions, but little is known about their
efficacy in obesity or T2DM and associated complications. In this
section, we will discuss some of these targets.
CC-chemokine ligand 2 and CCL5 are key mediators of
monocyte recruitment induced by high glucose levels via their
receptor CCR2 and CCR5 (Nunemaker et al., 2014). Oral
administration of RO5234444, a CCR2 antagonist, to db/db mice,
reduced infiltration of monocytes in the glomerulus, resulted
in preservation of glomeruli podocytes numbers and reduced
albuminuria (Sayyed et al., 2011). Similarly, intraperitoneal
administration of TAK-779, a dual inhibitor of chemokine
receptors CCR2 and CCR5, reduced macrophage infiltration
and expression of ICAM-1 in the retinas of STZ-diabetic
mice (Monickaraj et al., 2020). These studies clearly indicate
that blocking key recruitment chemokine receptors such as
CCR2 and/or CCR5 is a promising therapeutic avenue to
ameliorate common diabetic complications such as nephropathy
and retinopathy. Those compounds are currently pursued in
human clinical trials as well as others such as INCB8761/PF-
413630, which are a new series of CCR2 antagonists that are orally
bioavailable (Xue et al., 2011).
Due to their pro-inflammatory nature, IL-1β and TNFα
actions have been widely studied in many inflammatory
conditions and their blockade resulted in improvements in
T2DM-related conditions such as chronic kidney disease (Lei
et al., 2019) and pancreatic islet inflammation (Zha et al., 2016).
However, it remains unsure whether targeting these cytokines
affects leukocyte infiltration in peripheral tissues in T2DM.
Circulating levels of IL-1β are higher in T2DM (Reinehr et al.,
2016) and macrophages are the primary source of IL-1β in
obesity-induced inflammation (Gao et al., 2014). Administration
of LY2189102, a neutralizing IL-1β antibody, in patients with
T2DM, improved glycemic control and demonstrated significant
anti-inflammatory effects by lowering circulating IL-6 levels
when compared with placebo treatment (Sloan-Lancaster et al.,
2013). Moreover, islets from IL-1β-deficient mice exposed to high
glucose in vitro, produced lower IL-6 and chemokines compared
to wild-type islets (Ehses et al., 2009). Thus, efficacy of IL-
1β blocking on inflammatory biomarkers and glycemic control
raises the possibility of its use as a treatment in T2DM and other
inflammatory conditions.
Although, anti-TNFα is an approved medication for some
patients with rheumatoid arthritis (Katsumata et al., 2019), the
evidence showing the efficacy of this drug in T2DM is conflicting.
Indeed, anti-TNFα treatment using recombinant soluble TNFα
receptor-immuno-globulin G increased insulin sensitivity in
obese rodents (Hotamisligil et al., 1993). However, treatment with
Ro 45-2081, a TNFα antagonist (recombinant fusion protein that
consists of the soluble TNF-receptor linked to the Fc portion of
human IgG1), had no effect on blood glucose levels and insulin-
mediated glucose uptake in patients with T2DM (Paquot et al.,
2000). The inefficiency of Ro 45-2081 to control blood glucose
in patients with T2DM suggest that in addition its endocrine
action, TNFα may also act through an autocrine or paracrine
route. Consequently, sole neutralization of circulating TNFα
might not be enough to observe improvements on insulin action
(Paquot et al., 2000).
Anti-integrins
The importance of integrins in leukocyte adhesion and
arresting clearly offer potential therapeutical avenues in
relapsing inflammatory conditions such as rheumatoid arthritis
(von Andrian and Engelhardt, 2003) and multiple sclerosis
(Chaudhuri and Behan, 2003). Neutralization of integrins
has been tested in murine experimental models of diabetes,
particularly for the treatment and/or prevention of diabetic
complications (Barouch et al., 2000; Iliaki et al., 2009; Miyachi
et al., 2017). However, data showing efficacy in human clinical
trials is not available in the context of T2DM.
The expression of CD11a, CD11b, and CD18 integrins is
increased on the surface of neutrophils from STZ-induced
diabetic rats (Barouch et al., 2000). This increase was associated
with an enhanced adhesion of diabetic neutrophils to rat EC
monolayers in vitro. Pre-treatment of leukocytes with either
anti-CD11b or anti-CD18 antibodies significantly lowered the
proportion of adherent diabetic neutrophils (Barouch et al.,
2000). In the same study, systemic administration of anti-CD18
F(ab′)2 fragments to STZ-induced diabetic rats significantly
decreased diabetic retinal leukostasis (Barouch et al., 2000).
Furthermore, intraperitoneal administration of anti-α4 integrin
neutralizing antibody to a STZ-induced rat model of diabetes
retinopathy attenuated leukocyte adhesion to the retina and
suppressed TNFα expression and NF-κB activity in the retina
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of treated rats (Iliaki et al., 2009). Notably, blockage of VLA-
4 using a neutralizing antibody in HFD-fed mice attenuated
myeloid cell accumulation in the liver and improved systemic
glucose tolerance in treated mice compared to control HFD-
fed mice (Miyachi et al., 2017). Overall, all these animal data
identify the integrins as functional adhesive molecule in diabetic
complications and provides a potential target for the prevention
and/or treatment of the disease.
A humanized anti–VLA-4 monoclonal antibody
(Natalizumab) was clinically beneficial in the treatment of
Crohn’s disease (Lew and Stoffel, 2003), and rheumatoid arthritis
(von Andrian and Engelhardt, 2003). However, VLA-4 also
has key regulatory roles in immune response, including the
formation of the immune synapse (Mittelbrunn et al., 2004)
and the differentiation of Th1 T-cells (Isobe et al., 1997).
Obviously, the long-term administration of anti-integrins drugs
to patients with inflammatory conditions may have undesirable
or unexpected effects and more studies are required to fully
understand their action.
Fatty Acids
Long-chain n–3 polyunsaturated fatty acid (n–3 PUFA) such as
eicosatetraenoic acid (EPA) and docosahexaenoic acid (DHA),
found in marine fish oils, are able to down-regulate the activity
of NF-kB directly and therefore reduce the production of
inflammatory cytokines (Xu et al., 2001). n–3 PUFA can also
control leukocyte recruitment during inflammation and display
immunomodulatory properties (Yates et al., 2011). Inclusion
of n–3 PUFA in HFD prevented macrophage infiltration into
the adipose tissue of db/db mice (Todoric et al., 2006).
Interestingly, n–3 PUFA efficiently prevented the HFD-induced
downregulation of adiponectin circulating levels normally
observed in db/db (Todoric et al., 2006). These data therefore
suggest that the beneficial effects of n–3 PUFA on diabetes could
be mediated by their effect on adipose tissue inflammation, which
could in turn contribute to improving insulin sensitivity (Oliver
et al., 2010). However, much of the human evidence examining
the beneficial effects of n–3 PUFA in patients with T2DM have
limited follow-up periods (Vessby et al., 2001). As a result, it
is unclear whether n–3 PUFA supplementation has long lasting
beneficial effects and the exact mechanisms of n–3 PUFA action
and how they modulate the adipose tissue, macrophages and even
T-cells remain unknown.
Insulin
Several studies suggest a direct anti-inflammatory action of
insulin irrespectively of its glucose modulating capacity as
mentioned here in previous sections (Hyun et al., 2011). Insulin
was found to attenuates the activity of NF-κB and MCP-1
on human aortic ECs in vitro (Aljada et al., 2001). Insulin
infusion in individuals with obesity reduced plasma sICAM-1
and CCL2 levels (Dandona et al., 2001). In addition, treatment of
human monocytes with insulin in vitro promoted the secretion
of IL-8 (CXCL8), a potent chemoattractant for neutrophils
(Dandona et al., 2001). All together, these findings suggest a
possible regulatory effect of insulin on leukocyte trafficking
via regulating chemokine and cytokine secretion as well as
modulating adhesion molecules shedding. However, more studies
are required to clarify the effect of insulin on leukocyte migration
by including in vitro models taking into account the high glucose
levels observed in some patients with T2DM, their associated
complications and BMI to accurately determine the mechanism
of insulin action and lift the controversy in this field.
Adiponectin and PEPITEM
Since obesity is a key feature in T2DM, studies demonstrate
that changes in adipose tissue induce dysregulation in adipokines
such as adiponectin and receptors involved in lipid metabolism
such as Proliferator–activated receptor γ (PPAR-γ) (Bermudez
et al., 2010). Adiponectin is well characterized as an insulin-
sensitizing hormone as well as an anti-inflammatory adipokine
(Ruan and Dong, 2016). Circulating levels of adiponectin are
decreased in patients with obesity and T2DM (Hotta et al., 2000;
Engeli et al., 2003), suggesting that dysregulation of adiponectin
may be relevant to obesity-linked endothelial dysfunction in
these individuals (Cho et al., 2002; Katsiki et al., 2017). In
addition, adiponectin is also a regulator of adhesion molecules
on ECs (Ouchi et al., 1999). Treating ECs with adiponectin
inhibited the expression of adhesion molecules such as VCAM-
1, E-selectin, and ICAM-1 in vitro (Ouchi et al., 1999) and
in vivo (Ouedraogo et al., 2007). We also know that adiponectin
is able to regulate T-cell trafficking during inflammation in a
novel pathway characterized in our laboratory a few years ago
(Chimen et al., 2015). In this novel pathway, adiponectin induces
the release of the novel PEPtide Inhibitor of Trans-endothelial
Migration (PEPITEM) by B-cells via signaling through the
adiponectin receptors (AdipoR1/2). PEPITEM induces the
release of sphingosine-1-phosphate (S1P) by ECs via binding
with endothelial cadherin-15 (CDH15). In turn, S1P inhibits
T-cell transmigration by preventing integrin activation (Chimen
et al., 2015). The PEPITEM/Adiponectin pathway is dysregulated
in inflammatory conditions such as Type 1 Diabetes Melitus,
Rheumatoid Arthritis and in older adults. Dysregulation of this
pathway is caused by a lack of AdipoR1/2 expression on B-cells in
these patient groups leading to insufficient secretion of PEPITEM
and consequently allowing aberrant T-cell trafficking. PEPITEM
shows great therapeutic potential since it is an endogenous
peptide and developing strategies to restore this pathway could
help regain control on chronic inflammation. However, more
work is needed to understand the full profile of T-cell subsets
recruitment in adipose and pancreatic tissues in T2DM as this
would allow to characterize whether PEPITEM could be used as
a therapeutic avenue in T2DM.
PPAR Agonists
Proliferator–activated receptor-γ is a member of the PPAR family
of nuclear receptors (Braissant et al., 1996) and its activation is
associated with the induction of glucoregulatory molecules and
enhanced insulin sensitivity (Olefsky, 2000). Pioglitazone is a
PPARγ agonist that enhances the action of insulin mainly by
promoting glucose utilization in peripheral tissues (Yki-Järvinen,
2004). Treatment of patients with T2DM with pioglitazone
rapidly reduced systemic inflammation in those patients who
were also receiving angiotensin II receptor blockers. This trial
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also showed decreased CRP levels accompanied by a reduction
in sICAM-1 and sVCAM. These observations uncovered anti-
atherogenic effects of the PPAR-γ agonist which may also
contribute to a reduction of cardiovascular events in patients at
risk such as those with T2DM (Takase et al., 2007).
Current drugs such as IL-1β blockers and thiazolidinediones
targeting the metabolic side of T2DM and aiming to restore
glucose tolerance have shown to also have anti-inflammatory
effects (Yki-Järvinen, 2004; Sloan-Lancaster et al., 2013).
However, the evidence showing a potential effect of these drugs
on leukocyte recruitment as a way to control inflammation
are limited and this area needs further investigations. Blocking
cytokines such as TNF- α may reduce inflammation but also
renders the host susceptible to infection by silencing the danger
signals, which are necessary for adequate immune cell activation
(Rider et al., 2016) and maybe even to cancer (reviewed in
Dinarello, 2005). On the other hand, anti-cytokine therapy has
little or no organ toxicity or gastrointestinal disturbances and so
is well tolerated. Therefore, new site-restricted biologics which
block inflammatory cytokines only at sites of inflammation are
needed (Rider et al., 2016). In addition, it seems that targeting
inflammation in T2DM and obesity is promising but still only
show partial reduction of disease. This could be explained by
the fact that diabetes and obesity-mediated inflammation involve
multiple mechanisms and are not necessarily always linked to
hyperglycemia. This clearly highlights the need to identify how
anti-inflammatory treatments modulate glucose tolerance and
the complications associated with T2DM, but also an urgent
necessity to understand how inflammation is dysregulated in
T2DM and in obesity. More work is clearly required to fully
characterize the mechanisms behind the changes in leukocyte
phenotype and in local environments which directly influence
leukocyte migration. Finally, more specialistic studies from
leukocyte trafficking groups are needed to entirely determine
the changes in leukocyte migratory capacity and behaviors
in vitro and in vivo to complete the findings showing changes in
expression profiles such as those of adhesion molecules.
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